The CSM declined to grant a licence for Serum Cholinesterase. Read more about The CSM declined to grant a licence for Serum Cholinesterase.
The British Pharmacopoeia did not contain references the risk of AIDs associated with the use of commercial factor concentrates between 1983 and 1985. Read more about The British Pharmacopoeia did not contain references the risk of AIDs associated with the use of commercial factor concentrates between 1983 and 1985.
In an affidavit, Professor Adolf Asscher stated that there was an established process of investigating reports of serious adverse reactions. Read more about In an affidavit, Professor Adolf Asscher stated that there was an established process of investigating reports of serious adverse reactions.
Between 1970 and 1995 the Yellow Card reporting scheme for adverse drug reactions was limited to medical practitioners. Read more about Between 1970 and 1995 the Yellow Card reporting scheme for adverse drug reactions was limited to medical practitioners.
Dr Frances Rotblat (DHSS) was recorded as having told Cutter that it was extremely rare for the yellow card system for reporting adverse reactions to be used for hepatitis in blood products. Read more about Dr Frances Rotblat (DHSS) was recorded as having told Cutter that it was extremely rare for the yellow card system for reporting adverse reactions to be used for hepatitis in blood products.
Immuno made an application for Kryobulin TIM 2. Read more about Immuno made an application for Kryobulin TIM 2.
The DHSS began to collect data on the ability of heat-treated blood products to inactivate HIV. Read more about The DHSS began to collect data on the ability of heat-treated blood products to inactivate HIV.
An internal Cutter memo stated that AIDs had caused a virtual panic in the Department of Health, and that the Department had blocked every application for registration of heat-treated Factor 8 for a year. Read more about An internal Cutter memo stated that AIDs had caused a virtual panic in the Department of Health, and that the Department had blocked every application for registration of heat-treated Factor 8 for a year.
In a letter to R Nicholson (Immuno), M E Duncan (DHSS) confirmed that the Licensing Authority encouraged pharmaceutical companies to use a dry heat treatment process. Read more about In a letter to R Nicholson (Immuno), M E Duncan (DHSS) confirmed that the Licensing Authority encouraged pharmaceutical companies to use a dry heat treatment process.
At a meeting of the CSM(B), Dr Smith reported that preliminary evidence suggested that heat treatment would reduce the potential of transmitting AIDs via blood products. Read more about At a meeting of the CSM(B), Dr Smith reported that preliminary evidence suggested that heat treatment would reduce the potential of transmitting AIDs via blood products.